Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Medistim sets up UK business to maximise British interest in NICE recommended TTFM system

Medistim UK : 29 October, 2012  (Company News)
Medistim, a medical equipment supplier to cardiac and vascular surgeons as well as other medical specialists, is setting up a UK subsidiary.
Medistim sets up UK business to maximise British interest in NICE recommended TTFM system


The UK company, based in Gatwick, Sussex, will be boosted by a direct sales force - previously the company used distributors. The move strengthens Medistim's commitment to the UK market following the National Institute for Health and Clinical Excellence (NICE) recommendation of its innovative VeriQ flow measurement system for routine clinical use and cost savings of more than £115 per patient.



New Managing Director of Medistim UK, Roger Morberg, who previously worked for Siemens, Hewlett Packard and GE Healthcare, commented: "Medistim is very experienced in direct sales and support to its end customers through its subsidiaries in the USA, Germany and Denmark, and is well equipped to ensure a similarly successful direct operation in the UK. We are greatly looking forward to introducing the groundbreaking VeriQ system into routine clinical cardiac surgery."



Medistim President and Chief Executive Officer, Kari Krogstad, added: "We have received considerable interest from many UK cardiac centres in using our VeriQ flow measurement system following the NICE recommendation for assessing graft blood flow during coronary artery bypass graft surgery. The new UK office will enable us to ensure that all our customers are receiving the very best direct service and support and establish the benefits of flow measurement to surgeons as well as patients in the UK."



The Medistim VeriQ system uses two well-established ultrasound principles to measure graft patency in coronary artery bypass graft surgery (CABG); transit time flow measurement (TTFM) and Doppler velocity. The technology has been widely and successfully implemented in many countries, including Germany, Spain, the Nordic countries and Japan.



NICE has accepted the health economics derived from routine usage of the VeriQ system for assessing graft blood flow during coronary artery bypass graft (CABG) surgery, compared to clinical assessment alone, reporting an estimated cost saving of more than £115 per patient. NICE also supported the clinical evidence, suggesting reduction of early graft failure, stroke, myocardial infarction or recurrent angina.



In order to assess the impact of the adoption of this technology in the UK, the Medical Technology Advisory Committee of NICE conducted a review of the clinical evidence published on VeriQ and also carried out a full economic assessment of the impact of its use within the NHS. The findings of this review indicated that adoption of this technology in the NHS would have positive clinical and economic benefits, stating that, 'The case for adopting the VeriQ system in NHS for assessing graft flow during coronary artery bypass graft (CABG) surgery is supported by the evidence. The evidence suggests that intraoperative transit time flow measurement is effective in detecting imperfections that may be corrected by graft revision. This may reduce the incidence of graft occlusion and may reduce perioperative morbidity and mortality. The VeriQ system is associated with an estimated cost saving of £115 per patient compared with clinical assessment, when it is used routinely for assessing coronary artery bypass grafts during surgery'.



This follows the inclusion of graft patency verification with transit time flow measurement during CABG in the European 'Guidelines on Myocardial Revascularization' developed by ESC/EACTS.



"There are tremendous differences in clinical practice between European countries when it comes to graft patency verification during CABG, and the lack of utilisation of clinically proven, cost effective technology in many countries must be a concern, not only to patients and surgeons, but also to the payors," commented Kari Krogstad.



"Our expectations are that the NICE recommendations will enable UK surgeons to adopt the objective and reliable measurements offered by the VeriQ system. We also believe this endorsement has the potential to impact practice in many other countries, including the USA. Medistim is very encouraged by this news and continues our journey towards making blood flow measurement the standard of care in treating CABG patients all over the world."


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo